68Ga-DOTA/NOTA-FAPI-04

N/A

Report date: 2025/09/09 15:00:47

NME

Base Information

Drug Name68Ga-DOTA/NOTA-FAPI-04

Drug Alias NameN/A

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionDiagnostic imaging enhancersPositron-emission tomography enhancersRadionuclide imaging enhancers

TargetsNot applicable

Therapy Area/IndicationsFibrosisLiver CirrhosisNeoplasm Metastasis +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesFirst Affiliated Hospital Of Fujian Medical University

China Registration ClassN/A

Develop Information

Active CompaniesFirst Affiliated Hospital Of Fujian Medical University

Inactive CompaniesN/A

Active IndicationsFibrosis

Inactive IndicationsLiver CirrhosisNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A